{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T21:25:32Z","timestamp":1773350732273,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007833","name":"Hamad Medical Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007833","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40256-024-00628-6","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T10:02:40Z","timestamp":1708596160000},"page":"255-271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative Effectiveness and Safety of Direct Oral Anticoagulants Compared with Warfarin in Patients with Low Bodyweight who have Atrial Fibrillation: A\u00a0Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3229-6825","authenticated-orcid":false,"given":"Mohamed Nabil","family":"Elshafei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"El-Bardissy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Salem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed S.","family":"Abdelmoneim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherine","family":"Elhadad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Danjuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"628_CR1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa1105575","volume":"366","author":"JS Healey","year":"2012","unstructured":"Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau C, Fain E, Yang S, Bailleul C, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366:120\u20139.","journal-title":"N Engl J Med"},{"key":"628_CR2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1160\/TH10-01-0038","volume":"103","author":"GY Lip","year":"2010","unstructured":"Lip GY. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at \u2018moderate risk\u2019 [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb Haemost. 2010;103:683\u20135.","journal-title":"Thromb Haemost"},{"issue":"6","key":"628_CR3","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ, Huisman MV, Kearon C, King CS, Knighton AJ, Lake E, Murin S, Vintch JRE, Wells PS, Moores LK. Antithrombotic therapy for VTE disease: second update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160(6):e545\u2013608. https:\/\/doi.org\/10.1016\/j.chest.2021.07.055. (Epub 2021 Aug 2. Erratum in: Chest. 2022;162(1):269. PMID: 34352278).","journal-title":"Chest"},{"key":"628_CR4","doi-asserted-by":"crossref","unstructured":"Andreu, V. and J., P\u00e9rez- Rold\u00e1n V, L\u00f3pez-Fern\u00e1ndez MF. Pharmacogenetics of acenocoumarol in patients with extreme dose requirements. J Thromb Haemost. 1012, 2010. 8 SRC - BaiduScholar.","DOI":"10.1111\/j.1538-7836.2010.03800.x"},{"issue":"10","key":"628_CR5","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","volume":"165","author":"AM Holbrook","year":"2005","unstructured":"Holbrook AM, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095\u2013106.","journal-title":"Arch Intern Med"},{"issue":"6","key":"628_CR6","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1182\/blood-2006-09-049262","volume":"109","author":"E Sconce","year":"2007","unstructured":"Sconce E, et al. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood. 2007;109(6):2419\u201323.","journal-title":"Blood"},{"issue":"2","key":"628_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L. Antithrombotic therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315\u201352. https:\/\/doi.org\/10.1016\/j.chest.2015.11.026. (Epub 2016 Jan 7. Erratum in: Chest. 2016;150(4):988. PMID: 26867832.).","journal-title":"Chest"},{"key":"628_CR8","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022512orig1s000toc.cfm#:~:text=Approval%20Date%3A%2010%2F19%2F2010. Accessed 25 Jul 2023."},{"key":"628_CR9","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022406Orig1s000TOC.cfm. Accessed 25 July 2023."},{"key":"628_CR10","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/206316orig1orig2s000toc.cfm. Accessed 25 July 2023."},{"key":"628_CR11","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202155orig1s000toc.cfm. Accessed 25 July 2023."},{"issue":"9","key":"628_CR12","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799\u2013808.","journal-title":"N Engl J Med"},{"issue":"15","key":"628_CR13","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"VTEI Hokusai","year":"2013","unstructured":"Hokusai VTEI, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406\u201315.","journal-title":"N Engl J Med"},{"issue":"26","key":"628_CR14","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"E Investigators","year":"2010","unstructured":"Investigators E, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499\u2013510.","journal-title":"N Engl J Med"},{"issue":"14","key":"628_CR15","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","volume":"366","author":"EP Investigators","year":"2012","unstructured":"Investigators EP, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287\u201397.","journal-title":"N Engl J Med"},{"issue":"24","key":"628_CR16","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342\u201352.","journal-title":"N Engl J Med"},{"issue":"2","key":"628_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon C, et al. Antithrombotic therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315\u201352.","journal-title":"Chest"},{"issue":"6","key":"628_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/8755122516672693","volume":"32","author":"HM Phillippe","year":"2016","unstructured":"Phillippe HM, et al. Pharmacist interventions regarding the appropriateness of apixaban, rivaroxaban, dabigatran, and warfarin in a university-affiliated outpatient clinic. J Pharm Technol. 2016;32(6):245\u201352.","journal-title":"J Pharm Technol."},{"key":"628_CR19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1182\/asheducation-2013.1.464","volume":"2013","author":"KA Bauer","year":"2013","unstructured":"Bauer KA. Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2013;2013:464\u201370. https:\/\/doi.org\/10.1182\/asheducation-2013.1.464.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"628_CR20","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330\u201393.","journal-title":"Eur Heart J"},{"issue":"13","key":"628_CR21","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017559","volume":"9","author":"A Chen","year":"2020","unstructured":"Chen A, Stecker E, Warden AB. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13):e017559.","journal-title":"J Am Heart Assoc."},{"key":"628_CR22","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/jth.13701","volume":"15","author":"K Boonyawat","year":"2017","unstructured":"Boonyawat K, Caron F, Li A, Chai-Adisaksopha C, Lim W, Iorio A, Lopes RD, Garcia D, Crowther MA. Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis. J Thromb Haemost. 2017;15:1322\u201333.","journal-title":"J Thromb Haemost."},{"key":"628_CR23","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jacc.2018.11.051","volume":"73","author":"SR Lee","year":"2019","unstructured":"Lee SR, Choi EK, Park CS, Han KD, Jung JH, Oh S, Lip GYH. Direct oral anticoagulants in patients with nonvalvular atrial fibrillation and low body weight. J Am Coll Cardiol. 2019;73:919\u201331.","journal-title":"J Am Coll Cardiol."},{"key":"628_CR24","doi-asserted-by":"publisher","unstructured":"Covert K, Branam DL. Direct-acting oral anticoagulant use at extremes of body weight: literature review and recommendations. Am J Health Syst Pharm. 2020;77(11):865\u201376. https:\/\/doi.org\/10.1093\/ajhp\/zxaa059. (PMID: 32426845).","DOI":"10.1093\/ajhp\/zxaa059"},{"issue":"5","key":"628_CR25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jacep.2021.02.002","volume":"7","author":"AF Barakat","year":"2021","unstructured":"Barakat AF, Jain S, Masri A, Alkukhun L, Senussi M, Sezer A, Wang Y, Thoma F, Bhonsale A, Saba S, Mulukutla S. Outcomes of direct oral anticoagulants in atrial fibrillation patients across different body mass index categories. JACC Clin Electrophysiol. 2021;7(5):649\u201358. https:\/\/doi.org\/10.1016\/j.jacep.2021.02.002. (Epub 2021 Mar 31 PMID: 33812834).","journal-title":"JACC Clin Electrophysiol."},{"issue":"343","key":"628_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"18","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. Br Med J. 2011;18(343): d5928.","journal-title":"Br Med J"},{"key":"628_CR27","unstructured":"Wells GA, Shea B, O\u2019Connel D. et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Department of Epidemiology and Community Medicine, University of Ottawa, Canada; 2009; ohri.ca\/programs\/clinical_epidemiology\/oxford.htm"},{"key":"628_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001678","volume":"7","author":"N Koval","year":"2021","unstructured":"Koval N, Alves M, Pl\u00e1cido R, et al. Direct oral anticoagulants versus vitamin K antagonists in patients with antiphospholipid syndrome: systematic review and meta-analysis. RMD Open. 2021;7: e001678. https:\/\/doi.org\/10.1136\/rmdopen-2021-001678.","journal-title":"RMD Open"},{"issue":"12","key":"628_CR29","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351. https:\/\/doi.org\/10.1056\/NEJMoa0905561. (Epub 2009 Aug 30. Erratum in: N Engl J Med. 2010;363(19):1877).","journal-title":"N Engl J Med"},{"issue":"10","key":"628_CR30","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1009638. (Epub 2011 Aug 10).","journal-title":"N Engl J Med"},{"issue":"22","key":"628_CR31","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, \u0160pinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093\u2013104. https:\/\/doi.org\/10.1056\/NEJMoa1310907.","journal-title":"N Engl J Med"},{"issue":"12","key":"628_CR32","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1177\/2047487319886959","volume":"27","author":"E Berglund","year":"2020","unstructured":"Berglund E, Wallentin L, Oldgren J, Renlund H, Alexander JH, Granger CB, Hohnloser SH, Hylek EM, Lopes RD, McMurray JJ, Lytsy P. Effects of apixaban compared with warfarin as gain in event-free time\u2014a novel assessment of the results of the ARISTOTLE trial. Eur J Prev Cardiol. 2020;27(12):1311\u20139.","journal-title":"Eur J Prev Cardiol"},{"issue":"8","key":"628_CR33","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jacc.2018.11.051","volume":"73","author":"SR Lee","year":"2019","unstructured":"Lee SR, Choi EK, Park CS, Han KD, Jung JH, Oh S, Lip GYH. Direct oral anticoagulants in patients with nonvalvular atrial fibrillation and low body weight. J Am Coll Cardiol. 2019;73(8):919\u201331.","journal-title":"J Am Coll Cardiol."},{"issue":"11","key":"628_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13335","volume":"50","author":"V Russo","year":"2020","unstructured":"Russo V, Attena E, Di Maio M, Carbone A, Parisi V, Rago A, Grieco FV, Buonauro A, Golino P, Nigro G. Non-vitamin K vs vitamin K oral anticoagulants in patients aged > 80 year with atrial fibrillation and low body weight. Eur J Clin Invest. 2020;50(11):e13335.","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"628_CR35","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1161\/STROKEAHA.120.030356","volume":"52","author":"SR Lee","year":"2021","unstructured":"Lee SR, Choi EK, Jung JH, Park SH, Han KD, Oh S, Lip GYH. Body mass index and clinical outcomes in Asian patients with atrial fibrillation receiving oral anticoagulation. Stroke. 2021;52(2):521\u201330.","journal-title":"Stroke"},{"issue":"54","key":"628_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101709","volume":"31","author":"YM Nakao","year":"2022","unstructured":"Nakao YM, Nakao K, Wu J, Nadarajah R, Camm AJ, Gale CP. Risks and benefits of oral anticoagulants for stroke prophylaxis in atrial fibrillation according to body mass index: nationwide cohort study of primary care records in England. EClinicalMedicine. 2022;31(54): 101709.","journal-title":"EClinicalMedicine."},{"issue":"13","key":"628_CR37","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.3390\/jcm11133751","volume":"11","author":"V Russo","year":"2022","unstructured":"Russo V, Attena E, Baroni M, Trotta R, Manu MC, Kirchhof P, De Caterina R. Clinical performance of oral anticoagulants in elderly with atrial fibrillation and low body weight: insight into Italian cohort of PREFER-AF and PREFER-AF prolongation registries. J Clin Med. 2022;11(13):3751.","journal-title":"J Clin Med"},{"issue":"24","key":"628_CR38","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342\u201352.","journal-title":"N Engl J Med"},{"issue":"21","key":"628_CR39","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1182\/blood.V118.21.205.205","volume":"118","author":"S Schulman","year":"2011","unstructured":"Schulman S, Kakkar AK, Schellong SM, Goldhaber SZ, Henry E, Mismetti P, Christiansen AV, Schnee J, Kearon C. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood. 2011;118(21):205.","journal-title":"Blood"},{"issue":"8","key":"628_CR40","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1113697","volume":"368","author":"S Schulman","year":"2013","unstructured":"Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709\u201318.","journal-title":"N Engl J Med"},{"issue":"1","key":"628_CR41","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s11239-015-1310-7","volume":"41","author":"AE Burnett","year":"2016","unstructured":"Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016;41(1):206\u201332. https:\/\/doi.org\/10.1007\/s11239-015-1310-7.","journal-title":"J Thromb Thrombolysis"},{"issue":"10","key":"628_CR42","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Vanassche T, Potpara T, Camm AJ, Heidb\u00fcchel H, Lip GY, Deneke T, Dagres N, Boriani G, Field M. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612\u201376. https:\/\/doi.org\/10.1093\/europace\/euab065.","journal-title":"Europace"},{"issue":"1","key":"628_CR43","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12325-022-02333-9","volume":"40","author":"S Ballestri","year":"2023","unstructured":"Ballestri S, Romagnoli E, Arioli D, Coluccio V, Marrazzo A, Athanasiou A, Di Girolamo M, Cappi C, Marietta M, Capitelli M. Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review. Adv Ther. 2023;40(1):41\u201366. https:\/\/doi.org\/10.1007\/s12325-022-02333-9. (Epub 2022 Oct 16. PMID: 36244055; PMCID: PMC9569921).","journal-title":"Adv Ther"},{"issue":"11","key":"628_CR44","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392.","journal-title":"N Engl J Med"},{"key":"628_CR45","doi-asserted-by":"publisher","first-page":"j5058","DOI":"10.1136\/bmj.j5058","volume":"359","author":"JA L\u00f3pez-L\u00f3pez","year":"2017","unstructured":"L\u00f3pez-L\u00f3pez JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost effectiveness analysis. Br Med J. 2017;359:j5058.","journal-title":"Br Med J"},{"key":"628_CR46","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10654-018-0415-7","volume":"34","author":"G Li","year":"2019","unstructured":"Li G, Lip GYH, Holbrook A, et al. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Eur J Epidemiol. 2019;34:173\u201390.","journal-title":"Eur J Epidemiol"},{"key":"628_CR47","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s10654-021-00751-7","volume":"36","author":"J Zhang","year":"2021","unstructured":"Zhang J, Wang X, Liu X, et al. Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: a systematic review and meta-analysis. Eur J Epidemiol. 2021;36:793\u2013812. https:\/\/doi.org\/10.1007\/s10654-021-00751-7.","journal-title":"Eur J Epidemiol"},{"issue":"4","key":"628_CR48","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s10557-020-07122-6IF:3.4Q2","volume":"36","author":"M Grymonprez","year":"2022","unstructured":"Grymonprez M, De Backer TL, Steurbaut S, Boussery K, Lahousse L. Non-vitamin K antagonist oral anticoagulants (NOACs) versus warfarin in patients with atrial fibrillation and (morbid) obesity or low body weight: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2022;36(4):749\u201361. https:\/\/doi.org\/10.1007\/s10557-020-07122-6IF:3.4Q2.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"7","key":"628_CR49","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/jth.13701","volume":"15","author":"K Boonyawat","year":"2017","unstructured":"Boonyawat K, Caron F, Li A, et al. Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis. J Thromb Haemost. 2017;15(7):1322\u201333. https:\/\/doi.org\/10.1111\/jth.13701.","journal-title":"J Thromb Haemost"},{"key":"628_CR50","doi-asserted-by":"publisher","first-page":"103610","DOI":"10.1016\/j.amsu.2022.103610","volume":"77","author":"T Almas","year":"2022","unstructured":"Almas T, Muhammad F, Siddiqui L, et al. Safety and efficacy of direct oral anticoagulants in comparison with warfarin across different BMI ranges: a systematic review and meta-analysis. Ann Med Surg (Lond). 2022;77:103610. https:\/\/doi.org\/10.1016\/j.amsu.2022.103610.","journal-title":"Ann Med Surg (Lond)."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00628-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00628-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00628-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T16:25:50Z","timestamp":1711556750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00628-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["628"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00628-6","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]},"assertion":[{"value":"14 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding provided by the Qatar National Library. Apart from the publication fund provided by QNL, no other funding was sought for the conduction of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mohamed Nabil Elshafei, Muhammad Salem, Ahmed El-Bardissy, Mohamed S Abdelmoneim, Ahmed Khalil, Sherine Elhadad, and Mohammed Danjuma declare no conflicts of interest relevant to this review or its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"None is sought or required, as this is a secondary synthesis of already available data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"ME, MAM, and AE agreed on the review idea. ME and MS performed the initial search, screening, and data extraction. MA, AE, MS, and ME extracted data. ME and MID constructed the tables. ME and MD analyzed the data. ME produced the figures. ME, AE, MD, and MA wrote the initial manuscript. The manuscript was then critically revised by ME, MID, and AE. All the authors approved the final version of the manuscript for publication.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s Contributions"}},{"value":"All the data generated or analyzed during this study are included in the publication article.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}}]}}